Global Oncology Drugs Market Opportunities and Strategies to 2030 with COVID-19 Impact and Recovery Insights – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Oncology Drugs Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery” report has been added to ResearchAndMarkets.com’s offering.

The global oncology drugs market reached a value of nearly $167.9 billion in 2019, having increased at a compound annual growth rate (CAGR) of 9.8% since 2015. The market is expected to decline from $167.9 billion in 2019 to $149.9 billion in 2020 at a rate of -11%.

The decline is mainly due to lockdown and social distancing norms imposed by various countries and economic slowdown across countries owing to the COVID-19 outbreak and the measures to contain it. The market is expected to grow slightly from $201.1 billion in 2021 to $284.5 billion in 2023 at a CAGR of 9.7%. The market is expected to stabilize and reach $284.5 billion in 2025 and $412.9 billion in 2030.

Growth in the historic period resulted from rapid growth in elderly population, strong economic growth in emerging markets, increased healthcare expenditure, increased number of approvals for hematology/oncology (cancer) drugs, increase in pharmaceutical R&D expenditure and advances in cancer drug discovery. (Read more…) Factors that negatively affected growth in the historic period were patent expiration of drugs, pricing pressures from regulators, challenges due to regulatory changes, and low healthcare access.

Going forward, increase in cancer incidence rate, rise in healthcare expenditure, increasing geriatric population, strong pipeline of drugs and revised FDA regulations to facilitate biologics drug development are expected to drive the market. High costs of drugs, rise in interest rates, rising popularity of alternative therapies and natural remedies, coronavirus pandemic, covid-19 impacting drug trails, and reduction in free trade are major factors that could hinder the growth of the oncology drugs market in the future.

The oncology drugs market is segmented by type into drugs for lung cancer, pancreatic cancer, breast cancer, prostate cancer, ovarian cancer, colorectal cancer, gastric cancer, kidney cancer, brain tumor, thyroid cancer, skin cancer, bladder cancer, cervical cancer, blood cancer and others. The blood cancer was the largest segment of the oncology drugs market by type, accounting for 19.0% of the total market in 2019. Going forward, ovarian cancer segment is expected to be the fastest growing segment in the oncology drugs market, at a CAGR of 21.0%.

The oncology drugs market is also segmented by drug class type into targeted therapy, immunotherapy (biologic therapy), chemotherapy and hormonal therapy. The targeted therapy was the largest segment of the oncology drugs market by drug class type, accounting for 42.3% of the total market in 2019. Going forward, the chemotherapy segment is expected to be the fastest growing segment in the oncology drugs market, at a CAGR of 14.5%.

The oncology drugs market is also segmented by distribution channel into hospital pharmacies, retail pharmacies/drug stores and others. The hospital pharmacies was the largest segment of the oncology drugs market by distribution channel, accounting for 50.8% of the total market in 2019. Going forward, the others segment is expected to be the fastest growing segment in the oncology drugs market, at a CAGR of 12.6%.

The oncology drugs market is also segmented by route of administration into oral, parental and others. The parental was the largest segment of the oncology drugs market by route of administration, accounting for 53.5% of the total market in 2019. Going forward, the others segment is expected to be the fastest growing segment in the oncology drugs market, at a CAGR of 12.7%.

The oncology drugs market is also segmented by drug classification into branded drugs and generic drugs. The branded drugs was the largest segment of the oncology drugs market by drug classification, accounting for 94.3% of the total market in 2019. Going forward, the generic drugs segment is expected to be the fastest growing segment in the oncology drugs market, at a CAGR of 11.8%.

Key Topics Covered:

1. Oncology Drugs Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction

6.1.1. Segmentation By Geography

6.1.2. Segmentation By Type

6.1.3. Segmentation By Drug Class Type

6.1.4. Segmentation By Distribution Channel

6.1.5. Segmentation By Route Of Administration

6.1.6. Segmentation By Drug Classification

7. Oncology Drugs Market Characteristics

7.1. Market Definition

7.2. Market Segmentation By Type

7.2.1. Lung Cancer Drugs

7.2.2. Pancreatic Cancer Drugs

7.2.3. Breast Cancer Drugs

7.2.4. Prostate Cancer Drugs

7.2.5. Ovarian Cancer Drugs

7.2.6. Colorectal Cancer Drugs

7.2.7. Gastric Cancer Drugs

7.2.8. Kidney Cancer Drugs

7.2.9. Brain Tumor Drugs

7.2.10. Thyroid Cancer Drugs

7.2.11. Skin Cancer Drugs

7.2.12. Bladder Cancer Drugs

7.2.13. Cervical Cancer Drugs

7.2.14. Blood Cancer Drugs

7.2.15. Others

7.3. Market Segmentation By Drug Class Type

7.3.1. Chemotherapy

7.3.2. Targeted Therapy

7.3.3. Immunotherapy (Biologic Therapy)

7.3.4. Hormonal Therapy

7.4. Market Segmentation By Distribution Channel

7.4.1. Hospital Pharmacies

7.4.2. Retail Pharmacies/Drug Stores

7.4.3. Other Pharmacies

7.5. Market Segmentation By Route Of Administration

7.5.1. Oral

7.5.2. Parenteral

7.5.3. Others

7.6. Market Segmentation By Drug Classification

7.6.1. Branded Drugs

7.6.2. Generic Drugs

8. Oncology Drugs Market, Supply Chain Analysis

8.1. Raw Material Suppliers

8.2. Contract Research Organization (CRO)

8.3. Oncology Drugs Manufacturer

8.3.1. Drug Discovery

8.3.2. Preclinical And Clinical Trials

8.3.3. Patents Upon Discovery And Approval

8.3.4. Drug Manufacturing

8.4. Contract Manufacturing Organization (CMO)

8.5. Wholesalers/Distributors

8.6. Retailers (Pharmacies) And Hospitals

8.7. Oncologists

8.8. End-Users

9. Oncology Drugs Market, Product Analysis – Product Examples

10. Oncology Drugs Market Customer Information

10.1. Cancer Patients Need More Knowledge On Their Treatment

10.2. COVID-19 Pandemic Effects On Cancer Patients and Survivors

10.3. Pharma Salespeople Are A Major Influence On Oncologists

10.4. Only 17% Of Cancer Patients Are Treated Right

10.5. Major Challenges To Future Cancer Program Growth

10.6. Americans Taking More Prescription Drugs than Ever

10.7. Dutch Patients Highly Satisfied With Information On Chemotherapy

11. Oncology Drugs Market Trends And Strategies

11.1. Development And Increasing Demand For Next Generation Biologics

11.2. Innovation in Patient Therapies (New Active Substances)

11.3. CRISPR-Cas9 Technology Use In Cancer Treatment

11.4. Expansion Of Cell And Gene Therapy & CAR-T Approvals

11.5. Microneedle Pills

11.6. Development Of Personalized Cancer Vaccines

11.7. Rising Focus On Immunotherapy Drugs For Cancer Treatment

11.8. Development Of New Drugs To Treat Blood Cancer

11.9. Collaboration Driving Innovation

11.10. Investment In Artificial Intelligence For Oncology Drugs

11.11. Use Of 3D Printing To Test New Oncology Drugs

11.12. Rising Focus On Targeted Therapy

11.13. Shift Towards Oral Chemotherapy Drugs

12. Leading Oncology Drug Therapies

12.1. Chemotherapy

12.2. Targeted Therapy

12.3. Immunotherapy (Biologic Therapy)

12.4. Hormonal Therapy

12.5. Radiation Therapy

13. Gene Therapy In Oncology

13.1. Artificial Cell Stimulation

13.2. Oncolytic Virotherapy

13.3. Gene Transfer

13.4. Others

14. Unmet Needs In Oncology Drugs

14.1. Novel Mechanism Of Action

14.2. Less Treatment Options Available For Rare Cancers

14.3. Unfavorable Benefits/Risk

14.4. Intractable Tumors

14.5. Intractable Tumors Subsets

14.6. Rare Or Unclassifiable Tumors

15. Oncology Drugs In Pipeline

16. Top 10 Drugs In The Global Oncology drugs Market

17. COVID Impact On The Oncology Drugs Market

17.1. Clinical Trial Delays

17.2. Low Usage Of Drugs

17.3. Supply Chain Issues

18. Global Oncology Drugs Market Size And Growth

18.1. Market Size

18.2. Historic Market Growth, 2015 – 2019, Value ($ Billion)

18.2.1. Drivers Of The Market 2015 – 2019

18.2.2. Restraints On The Market 2015 – 2019

18.3. Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Billion)

18.3.1. Drivers Of The Market 2019 – 2023

18.3.2. Restraints On The Market 2019 – 2023

Companies Mentioned

• Novartis AG
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Johnson & Johnson
• Pfizer Inc.

For more information about this report visit https://www.researchandmarkets.com/r/pj9vgu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900